Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Nanoform Finland Oyj
  6. News
  7. Summary
    NANOFH   FI4000330972

NANOFORM FINLAND OYJ

(NANOFH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nanoform Finland Plc : - Manager's transactions - Gonšalo Andrade

09/24/2021 | 10:31am EST

Company release

Nanoform Finland Plc

Sep 24th, 2021

05.30 p.m. Finnish time / 04.30 p.m. Swedish time

Nanoform Finland Plc - Manager's transactions - Gonçalo Andrade

Manager's transaction related to Nanoform Finland Plc's other senior manager Gonçalo Andrade's disposal of shares.

____________________________________________

Person subject to the notification requirement

Name: Gonçalo Andrade

Position: Other senior manager

Issuer: Nanoform Finland Plc

LEI: 743700JJO2NU8LBS1592

Notification type: INITIAL NOTIFICATION

Reference number: 743700JJO2NU8LBS1592_20210924162537_2

____________________________________________

Transaction date: 2021-09-24

Venue not applicable

Instrument type: SHARE

ISIN: FI4000330972

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 2,000 Unit price: 7.86 EUR

(2): Volume: 2,000 Unit price: 7.82 EUR

(3): Volume: 2,000 Unit price: 7.8915 EUR

Aggregated transactions

(1): Volume: 6,000 Volume weighted average price: 7.8517 EUR

For further information, please contact:

Peter Hänninen, General Counsel

peter.hanninen@nanoform.com / +358 50 353 0408

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com / +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information please visit http://www.nanoform.com

https://news.cision.com/nanoform/r/nanoform-finland-plc---manager-s-transactions---goncalo-andrade,c3421388

https://mb.cision.com/Main/18905/3421388/1472962.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about NANOFORM FINLAND OYJ
11/25NANOFORM FINLAND OYJ : Interim Report January – September 2021
PU
11/25Nanoform Interim Report January - September 2021
AQ
11/25Nanoform Finland Oyj Reports Earnings Results for the Third Quarter and Nine Months End..
CI
11/18NANOFORM FINLAND OYJ : Interim Report for January-September 2021 – Report
PU
11/17Resolutions of Nanoform Finland Plc's Extraordinary General Meeting on November 17, 202..
AQ
11/17Nanoform Finland Oyj Elects Jeanne Thoma as New Member of the Board
CI
11/17Nanoform wins Star of Innovation award at the European Small and Mid-Cap Awards 2021
AQ
11/15Nanoform signs GMP agreement and achieves near-term business target
AQ
11/15Nanoform Signs GMP Agreement and Achieves Near-Term Business Target
CI
11/12NANOFORM RECEIVES ISO/IEC 27001 : 2013 certification for its Information Security Manageme..
AQ
More news
Financials
Sales 2021 2,05 M 2,32 M 2,32 M
Net income 2021 -20,2 M -22,9 M -22,9 M
Net cash 2021 70,2 M 79,5 M 79,5 M
P/E ratio 2021 -23,1x
Yield 2021 -
Capitalization 486 M 550 M 550 M
EV / Sales 2021 203x
EV / Sales 2022 52,4x
Nbr of Employees 116
Free-Float 71,2%
Chart NANOFORM FINLAND OYJ
Duration : Period :
Nanoform Finland Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOFORM FINLAND OYJ
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 6,70 €
Average target price 9,15 €
Spread / Average Target 36,6%
EPS Revisions
Managers and Directors
Edward HŠggstr÷m Chief Executive Officer
Albert Hńggstr÷m Chief Financial Officer & Director
Miguel Maria de Oliveira Barreiros Calado Chairman
Niklas Sandler Chief Technology Officer
Gonšalo Nuno N. da Silva Rebelo de Andrade Chief Business Operations
Sector and Competitors
1st jan.Capi. (M$)
NANOFORM FINLAND OYJ-5.37%550
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049